Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals (Nasdaq: RIGL) is a biotechnology company that develops and commercializes therapies for hematologic disorders and cancer, focusing on drugs that target disease-related signaling pathways. Its marketed products are TAVALISSE (fostamatinib), an oral SYK inhibitor for adults with chronic immune… From the company’s description.
Over the twelve months to Sep 30, 2026, Rigel Pharmaceuticals Inc. reported revenue of $288.21M, up 2.2% from a year earlier, and net income of $307.19M. Its operating margin was 26.3%, and operations generated $89.92M in cash. In fiscal 2025, it reported revenue of $294.28M, up 64.1% from fiscal 2024, and net income of $367.02M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rigel Pharmaceuticals Inc. does
In the company’s own words
Rigel Pharmaceuticals (Nasdaq: RIGL) is a biotechnology company that develops and commercializes therapies for hematologic disorders and cancer, focusing on drugs that target disease-related signaling pathways. Its marketed products are TAVALISSE (fostamatinib), an oral SYK inhibitor for adults with chronic immune thrombocytopenia; REZLIDHIA (olutasidenib), an oral IDH1 inhibitor for adults with relapsed or refractory AML with a susceptible IDH1 mutation; and GAVRETO (pralsetinib), an oral RET inhibitor for metastatic RET fusion-positive non-small cell lung cancer and certain advanced thyroid cancers. Rigel markets its products in the United States and works with licensees and partners to commercialize products internationally. Its development pipeline includes R289, an IRAK1/4 inhibitor being studied in lower-risk myelodysplastic syndrome, and programs evaluating olutasidenib in additional cancers; Eli Lilly leads development of the RIPK1 inhibitor ocadusertib. In fiscal 2025, net product sales were $158.8 million for TAVALISSE, $31.0 million for REZLIDHIA and $42.1 million for GAVRETO.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1034842
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rigel Pharmaceuticals Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rigel Pharmaceuticals Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rigel Pharmaceuticals Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rigel Pharmaceuticals Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rigel Pharmaceuticals Inc.'s last four quarterly filings that the numbers alone won't show?”